ENDRA Life Sciences Inc. (NDRA) News
Filter NDRA News Items
NDRA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest NDRA News From Around the Web
Below are the latest news stories about ENDRA LIFE SCIENCES INC that investors may wish to consider to help them evaluate NDRA as an investment opportunity.
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price RequirementANN ARBOR, Mich., November 22, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC ("Nasdaq"). |
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business UpdateANN ARBOR, Mich., November 15, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update. |
Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024ANN ARBOR, Mich., November 12, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a poster titled "Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity" for presentation at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Disease (AASLD), taking place November 15-19 in San Diego. |
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European PatentANN ARBOR, Mich., November 06, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the ‘282 patent) titled "Method and System for Monitoring Tissue Temperature." |
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in GermanyANN ARBOR, Mich., October 22, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the activation of a post market clinical study and first patient scanned with the TAEUS liver system at LMU University Hospital in Munich, one of the leading medical research centers in Europe. |
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing RequirementsANN ARBOR, Mich., August 28, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC ("Nasdaq") that the Nasdaq Hearings Panel (the "Panel") has granted the Company’s request for an extension through November 20, 2024, to evidence compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. |
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business UpdateANN ARBOR, Mich., August 22, 2024--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), reports financial results for the three and six months ended June 30, 2024, as filed in a Form 10-Q on August 14, 2024, and provides the following business update: |
ENDRA Life Sciences Announces Reverse Stock SplitANN ARBOR, Mich., August 16, 2024--ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the "Reverse Stock Split"), effective at 12:01 a.m. Eastern time on August 20, 2024. The Company’s common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, August 20, 2024, and will continue to trad |
ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024ANN ARBOR, Mich., August 13, 2024--ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024. |
ENDRA Life Sciences Announces Leadership ChangesANN ARBOR, Mich., August 13, 2024--ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced its Board of Directors has appointed Alexander Tokman as acting Chief Executive Officer to replace Francois Michelon, who stepped down from his role as Chief Executive Officer and as a member of the Board of Directors to pursue other endeavors. The Company also announced the addition to its senior management team of Ziad Rouag as Head of |